Long-Term Outcomes of Dabrafenib and Trametinib Combination in Stage III Melanoma with BRAF Mutation
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on December 16th, 2024
|
BRAF is a key gene involved in regulating cell growth, and mutations in this gene can lead to persistent MEK activation, causing uncontrolled cell proliferation, which is commonly seen in many melanoma cases. This condition can be managed by inhibiting both BRAF and MEK using dabrafenib and trametinib, in combination with other immunotherapy treatments that help clear cancerous tissue. Following FDA approval for use in 2018, long-term monitoring of patient health outcomes continued, and recent findings were published in the New England Journal of Medicine.
The study included 870 patients previously diagnosed with stage III melanoma harboring a mutation at the 600th amino acid residue of the BRAF protein (valine). The patients were randomly assigned to receive either a placebo or a combination of dabrafenib and trametinib for 12 months. Dabrafenib was administered at a dose of 150 mg twice daily, while trametinib was given once daily at a dose of 2 mg. After a median follow-up of 8.33 years, the researchers found that patients treated with dabrafenib and trametinib had a slightly higher survival rate than those receiving the placebo, though the difference was not statistically significant. Furthermore, the treatment regimen was effective in preventing relapse and metastasis. The researchers noted that the treatment was less effective in maintaining survival for patients with the valine-to-lysine (V600K) BRAF mutation, which could be attributed to the higher tumor burden associated with this mutation compared to the more common valine-to-glutamate (V600E) mutation.
The study included 870 patients previously diagnosed with stage III melanoma harboring a mutation at the 600th amino acid residue of the BRAF protein (valine). The patients were randomly assigned to receive either a placebo or a combination of dabrafenib and trametinib for 12 months. Dabrafenib was administered at a dose of 150 mg twice daily, while trametinib was given once daily at a dose of 2 mg. After a median follow-up of 8.33 years, the researchers found that patients treated with dabrafenib and trametinib had a slightly higher survival rate than those receiving the placebo, though the difference was not statistically significant. Furthermore, the treatment regimen was effective in preventing relapse and metastasis. The researchers noted that the treatment was less effective in maintaining survival for patients with the valine-to-lysine (V600K) BRAF mutation, which could be attributed to the higher tumor burden associated with this mutation compared to the more common valine-to-glutamate (V600E) mutation.